Comparison of prevalent management options to treat acute central serous chorioretinopathy

被引:0
|
作者
Pradhan, Atish K. [1 ]
Behera, Umesh C. [1 ,2 ]
机构
[1] LV Prasad Eye Inst, Retina Vitreous Serv, Anant Bajaj Retina Inst, Mithu Tulsi Chanrai Campus, Bhubaneswar, Odisha, India
[2] LV Prasad Eye Inst, Bhubaneswar 751024, Odisha, India
关键词
Acute; central serous chorioretinopathy; lasers; natural history; placebo treatment; RISK-FACTORS; FINASTERIDE; DETACHMENT; EPLERENONE; UPDATE;
D O I
10.4103/IJO.IJO_677_23
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To study the acute central serous chorioretinopathy (CSC) management strategies practiced at a tertiary eye care center in eastern India. Methods: In a retrospective chart review study, the clinical outcomes of three different management approaches to treating acute CSC were analyzed. Individuals with follow-ups of fewer than 6 months were excluded. Logistic regression analysis was performed to identify the prognostic markers of CSC resolution. Results: In the 10-year study period (January 2013-July 2022), 206 eyes were included. Placebo treatment was the preferred practice (48.5%; n = 100 eyes). Watchful observation without placebo was the management strategy in 30.6% (n = 63) of the eyes, and 20.9% (n = 43) of eyes received focal lasers. Risk factor modification was attempted in all. There was no significant difference in the resolution rate (P = 0.819), time to resolution (P = 0.331), and disease recurrence (P = 0.067) among the groups. Univariate logistic regression analysis did not favor any of the treatment strategies predicting resolution and recurrence. Conclusion: Alternative treatment modes did not score over the natural history of acute CSC regarding disease resolution, vision gain, and disease recurrence. The study reaffirms observation as the standard of care for acute CSC.
引用
收藏
页码:3563 / 3568
页数:6
相关论文
共 50 条
  • [21] Light exposure in acute central serous chorioretinopathy
    Norouzpour, Amir
    EYE, 2022, 36 (01) : 243 - 243
  • [22] Light exposure in acute central serous chorioretinopathy
    Amir Norouzpour
    Eye, 2022, 36 : 243 - 243
  • [23] Acute central serous chorioretinopathy and fundus autofluorescence
    Eandi, CM
    Ober, M
    Iranmanesh, R
    Peiretti, E
    Yannuzzi, LA
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2005, 25 (08): : 989 - 993
  • [24] Acute Transverse Myelitis with Central Serous Chorioretinopathy
    Song, Hyun Seok
    Seo, Seong Don
    Park, Jin-Sung
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (07) : 951 - 951
  • [25] Clinical experience with eplerenone to treat chronic central serous chorioretinopathy
    Bertan Cakir
    Franziska Fischer
    Christoph Ehlken
    Anima Bühler
    Andreas Stahl
    Günther Schlunck
    Daniel Böhringer
    Hansjürgen Agostini
    Clemens Lange
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2016, 254 : 2151 - 2157
  • [26] Clinical experience with eplerenone to treat chronic central serous chorioretinopathy
    Cakir, Bertan
    Fischer, Franziska
    Ehlken, Christoph
    Buehler, Anima
    Stahl, Andreas
    Schlunck, Guenther
    Boehringer, Daniel
    Agostini, Hansjuergen
    Lange, Clemens
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2016, 254 (11) : 2151 - 2157
  • [27] Current Pharmacological Treatment Options for Central Serous Chorioretinopathy: A Review
    Nicolo, Massimo
    Desideri, Lorenzo Ferro
    Vagge, Aldo
    Traverso, Carlo Enrico
    PHARMACEUTICALS, 2020, 13 (10) : 1 - 16
  • [28] Role of Avastin in management of central serous chorioretinopathy
    Mehany, Shaaban A.
    Shawkat, Ahmad M.
    Sayed, Mohamed F.
    Mourad, Khaled M.
    SAUDI JOURNAL OF OPHTHALMOLOGY, 2010, 24 (03) : 69 - 75
  • [29] An Update on the Diagnosis and Management of Central Serous Chorioretinopathy
    Liu, David T.
    Fok, Andrew T.
    Lam, Dennis S. C.
    ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY, 2012, 1 (05): : 296 - 302
  • [30] CENTRAL SEROUS CHORIORETINOPATHY
    Samalia, Priya
    Chong, Cheefoong
    Riley, Andrew
    Squirrell, David
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2015, 43 : 111 - 112